Get the Stockscreener App
0.8322
5.82%
0.0458
Icecure Medical Ltd stock is traded at $0.8322, with a volume of 547.67K.
It is up +5.82% in the last 24 hours and up +34.23% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$0.7865
Open:
$0.78
24h Volume:
547.67K
Relative Volume:
0.83
Market Cap:
$43.85M
Revenue:
$2.91M
Net Income/Loss:
$-15.61M
P/E Ratio:
-2.1672
EPS:
-0.384
Net Cash Flow:
$-14.50M
1W Performance:
+38.12%
1M Performance:
+34.23%
6M Performance:
-19.20%
1Y Performance:
+12.46%
1-Day Range:
$0.78
$0.85
1-Week Range:
$0.56
$0.89
52-Week Range:
$0.48
$1.57
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
0.8322 | 43.85M | 2.91M | -15.61M | -14.50M | -0.384 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Icecure Medical Ltd Stock (ICCM) Latest News
IceCure Medical Ltd (NASDAQ:ICCM) Q3 2024 Earnings Call Transcript - Insider Monkey
IceCure Medical’s sales grow 36% in nine months of 2024 - Medical Buyer
IceCure Receives Notice of Allowance from U.S. Patent and Tradem - GuruFocus.com
IceCure Medical Sees Strong Growth Amid ProSense® Adoption - TipRanks
IceCure Medical Ltd Reports Earnings Results for the Nine Months Ended September 30, 2024 - Marketscreener.com
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - PR Newswire
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office - Yahoo Canada Finance
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 - PR Newswire
IceCure gets favorable FDA AdCom vote for ProSense System - MSN
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Au - GuruFocus.com
IceCure Medical Sets Q3 2024 Earnings Call Date; Cryoablation Developer to Update Investors | ICCM Stock News - StockTitan
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health - Marketscreener.com
IceCure's ProSense® Selected for Major European Breast Cancer Treatment Study | ICCM Stock News - StockTitan
Market Sentiment Around Loss-Making IceCure Medical Ltd (NASDAQ:ICCM) - Simply Wall St
Icecure wins advisory nod for Prosense system for breast cancer - BioWorld Online
IceCure’s cryoablation system for breast cancer treatment gains FDA panel support - Yahoo Finance
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer - The Malaysian Reserve
ICCMIceCure Medical Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Icecure Medical Ltd (ICCM) Is A Good Stock To Invest In - Stocks Register
IceCure's ProSense Cancer Treatment Wins Crucial FDA Panel Vote, Shares Surge | ICCM Stock News - StockTitan
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoabl - GuruFocus.com
IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023 - BioSpace
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - Marketscreener.com
Independent Study Results in Japan Demonstrate Zero (0%) Breast - GuruFocus.com
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 - GuruFocus.com
Globus Medical (NYSE:GMED) & IceCure Medical (NASDAQ:ICCM) Head-To-Head Contrast - Defense World
IceCure receives US patent allowance for cryoablation system - Investing.com
IceCure receives US patent allowance for cryoablation system By Investing.com - Investing.com Australia
IceCure Announces FDA Advisory Panel Meeting Date for Marketing - GuruFocus.com
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System - Marketscreener.com
Indo-Asian News Service - IANS India Pvt Ltd
Analytical Overview: Icecure Medical Ltd (ICCM)’s Ratios Tell a Financial Story - The Dwinnex
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablati - GuruFocus.com
Best Penny Stocks Under $1 To Buy Now - AOL
Icecure Medical Ltd (ICCM) shows promising results - US Post News
Ratios in Focus: Analyzing Icecure Medical Ltd (ICCM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
ICCM stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com UK
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference - StreetInsider.com
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Yahoo Finance
IceCure reports high success rate in breast cancer trial By Investing.com - Investing.com Australia
Ex-ad industry employees launch a new digital agency 'itch' - afaqs!
IceCure reports high success rate in breast cancer trial - Investing.com India
Why Is Interactive Strength Stock Surging Today? - Benzinga
InCred's Aditya Sood Reveals Key Factors Behind Selecting Indraprastha Medical From Hospital Sector - Business Today
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96 - StreetInsider.com
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate - PR Newswire
The time has not yet come to remove your chips from the table: Icecure Medical Ltd (ICCM) - SETE News
What will the future hold for Icecure Medical Ltd (NASDAQ:ICCM) stock? - US Post News
FDA AdComm to discuss IceCure's ProSense on Nov. 7 - MSN
Study: Liquid Nitrogen-Based Cryoablation Safe for Treating Treating Tumors of the Lung, Bone and Soft Tissues - Imaging Technology News
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):